Cargando…

Change in Insulin Sensitivity and Lipid Profile After Dopamine Agonist Therapy in Patients With Prolactinoma

Background Prolactinomas are prolactin(PRL)-secreting neoplastic lesions that can lead to metabolic disturbances and insulin resistance. We aimed to find the change in insulin sensitivity and lipid profile in prolactinoma patients after dopamine therapy. Methodology A prospective observational stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khalil, Ghayyur, Khan, Feroz A, Jamal, Qazi M, Saleem, Ayesha, Masroor, Hassan, Abbas, Kiran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2021
Materias:	Internal Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505009/ https://www.ncbi.nlm.nih.gov/pubmed/34660034 http://dx.doi.org/10.7759/cureus.17824

Ejemplares similares

Coinfection of Hepatitis B and Hepatitis C Virus in Patients With Human Immunodeficiency Virus
por: Masroor, Hassan, et al.
Publicado: (2021)

Outcomes of Mechanically Ventilated Patients With Nosocomial Tracheobronchitis
por: Khan, Feroz Ali, et al.
Publicado: (2021)

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
por: Liu, Xiaoshuang, et al.
Publicado: (2019)

Experience with Dopamine Agonists in the Treatment of Prolactinomas
por: Barabash, Nadiya Ye., et al.
Publicado: (2022)

Predictors of dopamine agonist resistance in prolactinoma patients
por: Vermeulen, Elle, et al.
Publicado: (2020)

Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management?
por: De Sousa, Sunita M C
Publicado: (2022)

Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists
por: Babey, Muriel, et al.
Publicado: (2010)

Dopamine agonist resistant prolactinomas: any alternative medical treatment?
por: Souteiro, P., et al.
Publicado: (2019)

Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists
por: Tang, Hao, et al.
Publicado: (2021)

Long-term Outcome of Microscopic Transsphenoidal Surgery for Prolactinomas as an Alternative to Dopamine Agonists
por: Park, Kawngwoo, et al.
Publicado: (2021)

PMON169 D2R Expression in Dopamine-Agonist Resistant Prolactinomas
por: Levine, Alice, et al.
Publicado: (2022)

Effect of Tamoxifen on the Management of Dopamine Agonist-Resistant Prolactinomas: A Systematic Review
por: Bazuhair, Tuqa, et al.
Publicado: (2023)

Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas
por: Gao, Hua, et al.
Publicado: (2015)

Prolactinomas Resistant to Treatment With Dopamine Agonists: Long-Term Follow-Up of Six Cases
por: Gonzaga, Maria de Fátima de Magalhães, et al.
Publicado: (2018)

SUN-448 Giant Prolactinomas: A Follow-Up of 25 Years with Dopamine Agonists
por: Mallea Gil, Susana, et al.
Publicado: (2019)

Metabolic effects of dopamine agonists in patients with prolactinomas: a systematic review and meta-analysis
por: Byberg, Sarah, et al.
Publicado: (2019)

The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis
por: Zou, Yunzhi, et al.
Publicado: (2021)

Morbid Obesity Due to Prolactinoma and Significant Weight Loss After Dopamine Agonist Treatment
por: Ali, Muzaffar, et al.
Publicado: (2021)

Status epilepticus induced by treatment with dopamine agonist therapy for giant prolactinoma: a case report
por: Koguchi, Motofumi, et al.
Publicado: (2019)

SAT-247 Use of Double Dopamine Agonists in Giant Prolactinomas: A Series of 6 Cases
por: Kuan, Yueh Chien
Publicado: (2020)

MON-293 The Prevalence of Impulse Control Disorders in Patients with Acromegaly and Prolactinomas Treated with Dopamine Agonists
por: Ozkaya, Hande Mefkure, et al.
Publicado: (2020)

FRI303 PRL-R Variants Are Not Only Associated With Prolactinomas But Also With Dopamine Agonist Resistance
por: de Castro Moreira, Andrea Ramos, et al.
Publicado: (2023)

Lost to Follow-Up: Complications of an Invasive Giant Prolactinoma
por: Blackmon, Melodie M, et al.
Publicado: (2020)

Delayed presentation of late-onset cerebrospinal fluid rhinorrhoea following dopamine agonist therapy for giant prolactinoma
por: Prague, J K, et al.
Publicado: (2014)

Pituitary Prolactinoma with Amyloid Deposits: Surgery or Dopamine Agonists? Review of Previous Reports and New Recommendations for Management
por: Prabhu, Santosh, et al.
Publicado: (2019)

The side effects of dopamine receptor agonist drugs in Chinese prolactinoma patients: a cross sectional study
por: Ke, Xiaoan, et al.
Publicado: (2022)

Successful Improvement of Metabolic Disorders, Including Osteopenia, by a Dopamine Agonist in a Male Patient with Macro-Prolactinoma
por: Takeno, Ayumu, et al.
Publicado: (2016)

The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas
por: Wang, Shuman, et al.
Publicado: (2021)

Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis
por: Cai, Xiangming, et al.
Publicado: (2022)

FRI305 Impulse Control Disorders In Patients With Prolactinomas And Non-Functioning Pituitary Adenomas Treated With Dopamine Agonists
por: Kolitz, Tamara, et al.
Publicado: (2023)

Is prolactin receptor signaling a target in dopamine-resistant prolactinomas?
por: Ferraris, Jimena
Publicado: (2023)

SAT-455 Analysis of a Group of Prolactinomas Resistant to Treatment with Dopamine Agonists at a University Hospital in Buenos Aires, Argentina
por: Gonzalez Pernas, Mariana, et al.
Publicado: (2019)

PMON78 Improvement in Resistant Hypogonadism with use of Clomiphene in Prolactinomas Treated with Dopamine Agonist: A Case Study and Review of Literature
por: Singh, Julie, et al.
Publicado: (2022)

Association of Lipid and Body Mass Index Profile With Chronic Hepatitis C Infection Stratified by Age and Gender
por: Maqsood, H, et al.
Publicado: (2021)

Acute Hepatitis in Infections Caused by Dengue Virus in Southern Punjab, Pakistan
por: Ishtiaq, Rizwan, et al.
Publicado: (2018)

Impact of Fasting Lipid Profile on Chronic Kidney Disease Patients Having Fatty Liver Disease
por: Asghar, Muhammad Sohaib, et al.
Publicado: (2020)

Expression of Stem Cell Markers and Dopamine D2 Receptors in Human and Rat Prolactinomas
por: Gao, Zhichao, et al.
Publicado: (2017)

SAT620 Dopamine Challenge: Treatment Of Pituitary Macroadenoma/Prolactinoma In Patient On Antipsychotic Medication
por: Bazhenov, Aleksei, et al.
Publicado: (2023)

Hereditary Tyrosinemia Compounded With Hyperinsulinemic Hypoglycemia: Challenging Diagnosis of a Rare Case
por: Nasir, Sharmeen, et al.
Publicado: (2020)

Rifaximin Therapy for Patients With Metronidazole-Unresponsive Clostridium difficile Infection
por: Waqas, Muhammad, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4g7rhkdsn3rfj41d8rrhotmb7m